Literature DB >> 30953357

AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway.

Minda Zhang1, Chenyu Jin1, Yunjia Yang1, Keke Wang1, Yunjiang Zhou1, Yang Zhou1, Rui Wang1, Tao Li1, Rong Hu1.   

Abstract

The human absent in melanoma 2 (AIM2) is considered as a DNA recognizer. AIM2 has been described as a tumor suppressor gene in the early years. But recent studies suggested that it functions as an oncogene in several cancers. However, its roles in non-small-cell lung cancer (NSCLC) remain unclear. Here we reported that AIM2 highly expressed in NSCLC cells and exhibited a tumor-promoting property both in vitro and in vivo. Besides, AIM2 short hairpin RNA (shRNA)-mediated suppression of cell proliferation was triggered by the accumulation of cells at the G2/M phase. Knockdown of AIM2 reduced the inflammasome formation, while overexpression of AIM2 or stimulation by poly(dA:dT) induced the inflammasome formation. Interestingly, blockade of the inflammasome by caspase-1 inhibitor VX-765 or ASC small interfering RNA (siRNA) abolished the effects brought by AIM2 shRNA and AIM2 plasmid. In summary, our results revealed that AIM2 functioned as an oncogene in NSCLC in an inflammasome-dependent way.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  AIM2; cell cycle; inflammasome; non-small-cell lung cancer

Mesh:

Substances:

Year:  2019        PMID: 30953357     DOI: 10.1002/jcp.28617

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

Review 1.  AIM2 in health and disease: Inflammasome and beyond.

Authors:  Puja Kumari; Ashley J Russo; Sonia Shivcharan; Vijay A Rathinam
Journal:  Immunol Rev       Date:  2020-07-26       Impact factor: 12.988

2.  AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics.

Authors:  Miao Qi; Dan Dai; Jin Liu; Zhongqi Li; Panpan Liang; Yue Wang; Lu Cheng; Yihong Zhan; Zhifeng An; Yaoyao Song; Yana Yang; Xiaohui Yan; Hui Xiao; Huanjie Shao
Journal:  Oncogene       Date:  2020-01-31       Impact factor: 9.867

3.  Molecular Subtypes and Prognostic Signature of Pyroptosis-Related lncRNAs in Glioma Patients.

Authors:  Guilong Tanzhu; Na Li; Zhanzhan Li; Rongrong Zhou; Liangfang Shen
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

4.  Identification of a Novel Pyroptosis-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Skin Cutaneous Melanoma.

Authors:  An-An Li; Yu Zhang; Wei-Lai Tong; Jiang-Wei Chen; Shan-Hu Huang; Jia-Ming Liu; Zhi-Li Liu
Journal:  Int J Gen Med       Date:  2022-07-12

5.  Expression of AIM2 in Rheumatoid Arthritis and Its Role on Fibroblast-Like Synoviocytes.

Authors:  Yong Chen; Qiu Fujuan; Ensheng Chen; Beijia Yu; Fangfang Zuo; Yi Yuan; Xiaofeng Zhao; Changhong Xiao
Journal:  Mediators Inflamm       Date:  2020-10-26       Impact factor: 4.711

6.  CircPSMC3 Suppresses Migration and Invasion of Non-Small Cell Lung Cancer Cells via miR-182-5p/NME2 Axis.

Authors:  Tao Xu; Yejun Yu; Shengcong Guo; Lixiang He; Zejun Mao
Journal:  Med Sci Monit       Date:  2020-05-09

7.  PVT1 Promotes Angiogenesis by Regulating miR-29c/Vascular Endothelial Growth Factor (VEGF) Signaling Pathway in Non-Small-Cell Lung Cancer (NSCLC).

Authors:  Zejun Mao; Botao Xu; Lixiang He; Guodong Zhang
Journal:  Med Sci Monit       Date:  2019-07-21

Review 8.  Inflammasome inhibitors: promising therapeutic approaches against cancer.

Authors:  Shengchao Xu; Xizhe Li; Yuanqi Liu; Yu Xia; Ruimin Chang; Chunfang Zhang
Journal:  J Hematol Oncol       Date:  2019-06-26       Impact factor: 17.388

9.  Prognostic Inflammasome-Related Signature Construction in Kidney Renal Clear Cell Carcinoma Based on a Pan-Cancer Landscape.

Authors:  Tianyu Zheng; Xindong Wang; Peipei Yue; Tongtong Han; Yue Hu; Biyao Wang; Baohong Zhao; Xinwen Zhang; Xu Yan
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-03       Impact factor: 2.629

Review 10.  The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer.

Authors:  Man Wang; Shuai Jiang; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.